Clinical trials: Urinary Bladder Overactive
Transcutaneous Electrical Nerve Stimulation, Urgent Urinary Incontinence
The Effectiveness of Parassacral Transcutaneous Stimulation Compared to Tibial Transcutaneous Stimulation, Home Protocol and Behavioral Therapy in the Treatment of Female Hyperative Bladder: Randomized Clinical Trial
Introduction: The overactive bladder is a highly prevalent condition, which negatively impacts the quality of life and daily activities of women.
- Conditions
- Transcutaneous Electrical Nerve Stimulation, Urgent Urinary Incontinence, Bladder Hyperactive, Women
- Trial name
- NCT04909047
- Testing
- parassacral transcutaneous electrostimulation
- Where
- 3 sites in Brazil
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centro de Atenção ao Assoalho Pélvico
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder, Quality of Life
Information, Motivation, Behavioral Skills Model on Urinary Incontinence and Quality of Life in Men
Multiple studies have shown that education based on the IMB model is effective at bringing about health-related behavior change.
- Trial name
- NCT04068025
- Testing
- Assigned Interventions
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Ankara Yildirim Beyazıt University
Overactive Bladder (OAB)
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.
- Trial name
- NCT03602508
- Testing
- mirabegron, solifenacin, darifenacin
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 5,589 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Urinary Incontinence, Overactive Bladder
Reliability of KHQ and ICIQ-SF in Assessing Urinary Incontinence Effects in Polish Women
The aim of this study was to assess the psychometric properties of KHQ and ICIQ-SF in polish women.
- Conditions
- Urinary Incontinence, Overactive Bladder, Stress Urinary Incontinence, Urge Incontinence
- Trial name
- NCT04619238
- Testing
- King's Health Questionnaire, the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form
- Where
- Poland
- Volunteers
- 155 people
- Sponsor
- Medical University of Lublin
Lower Urinary Tract Symptoms
LURN: Urinary Urgency Phenotyping Protocol
The purpose of this study is to define and characterize important subtypes of patients with urinary urgency to improve our understanding of the pathophysiology, risk factors, experiences, and comorbidities to lay the foundation…
- Trial name
- NCT04557748
- Testing
- Observational, Observational Controls, Central Sensitization
- Where
- 6 sites in United States
- Volunteers
- 1,030 people, healthy volunteers welcome
- Sponsor
- Arbor Research Collaborative for Health
Overactive Bladder, Urinary Urgency
Optimal Injection Interval for Intra-Detrusor Botulinum Toxin
The goal of this clinical trial is to see if patients deciding their own follow up times can increase the effectiveness of botulinum toxin (BTX or "Botox") injection for overactive bladder (OAB).
- Conditions
- Overactive Bladder, Urinary Urgency, Urinary Incontinence, Urge Urinary Incontinence
- Trial name
- NCT06483217
- Testing
- Patient-directed follow up
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Overactive Bladder Syndrome
Xeomin vs Botox for Treatment of Overactive Bladder Syndrome
Purpose: Multiple formulations and brands of botulinum toxin exist on the market today. Only OnabotulinumtoxinA (BOTOX®) is currently FDA approved for treatment of overactive bladder.
- Trial name
- NCT06034288
- Testing
- Xeomin 100 UNT Injection, Botox 100 UNT Injection
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Overactive Bladder Syndrome
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
Research question: A wealth of existing research has established the independent effectiveness of mirabegron and neuromodulation in the treatment of overactive bladder syndrome.
- Trial name
- NCT05188742
- Testing
- mirabegron, TTNS
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Overactive Bladder Syndrome
Study of V117957 in Overactive Bladder Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
- Trial name
- NCT06024642
- Testing
- V117957
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- Imbrium Therapeutics
Overactive Bladder
The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
The medical field is beginning to adopt treatments that alter an individual's microbiome to improve patient health; however, this approach has not been adopted for treatment of lower urinary tract symptoms (LUTS).
- Trial name
- NCT02524769
- Testing
- conjugated estrogen
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Loyola University
Overactive Bladder
Usability Study of the FemPulse System
The objective of the study is to demonstrate that the FemPulse System can be used as indicated in the Instructions for Use (IFU), as applicable.
- Trial name
- NCT06347380
- Testing
- FemPulse System
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- FemPulse Corporation
Overactive Bladder
A Safety Extension Study of DR-OXY-301
This is a safety extension study of DR-OXY-301 at pre-selected sites. Subjects who complete the DR-OXY-301 study are eligible to participate. The duration of this extension study will be up to approximately 42 weeks.
- Trial name
- NCT00782769
- Testing
- Oxybutinyn Vaginal Ring 4mg, Oxybutinyn Vaginal Ring 6mg
- Where
- 35 sites in United States
- Volunteers
- 240 people
- Sponsor
- Duramed Research
Urinary Bladder, Overactive
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive…
- Trial name
- NCT00613327
- Testing
- Oxybutynin chloride OROS
- Volunteers
- 345 people
- Sponsor
- Janssen Korea, Ltd., Korea
Overactive Bladder
Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
The purpose of this study is to determine whether the non-invasive neurostimulation patch is effective in the treatment of urgency, frequency and urge (urinary) incontinence.
- Trial name
- NCT01125722
- Testing
- Non-invasive neurostimulation device
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 74 people
- Sponsor
- Ethicon Endo-Surgery
Overactive Bladder
The Efficacy of Botulinum Toxin in OVERACTIVE Bladder
To assess the efficacy of botulinum toxin injection in overactive bladder.
- Trial name
- NCT03888001
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assiut University
Overactive Bladder, Painful Bladder Syndrome
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
Interstitial cystitis (IC)/chronic pelvic pain syndrome (CPPS) is a clinical syndrome of pelvic pain and/or urinary urgency/frequency in absence of a specific cause such as bacterial infection or damage to the bladder.
- Conditions
- Overactive Bladder, Painful Bladder Syndrome, Chronic Pelvic Pain Syndrome, Cystitis, Interstitial
- Trial name
- NCT00775281
- Where
- Switzerland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Overactive Bladder
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
The primary purpose of this study is to assess the efficacy and safety of THVD-201(Combination of tolterodine and pilocarpine) in patients with Overactive bladder during the period of treatment, 12 weeks.
- Trial name
- NCT02485067
- Testing
- THVD-201, Detrusitol 2mg tablet
- Where
- 16 sites in South Korea
- Volunteers
- 384 people
- Sponsor
- SK Chemicals Co., Ltd.
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.